과제정보
This work was supported by INHA UNIVERSITY Research Grant.
참고문헌
- Swann JB and Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117, 1137-1146 https://doi.org/10.1172/JCI31405
- Verma NK, Wong BHS, Poh ZS et al (2022) Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint. EBioMedicine 83, 104216
- Wang M, Wang S, Desai J, Trapani JA and Neeson PJ (2020) Therapeutic strategies to remodel immunologically cold tumors. Clin Transl Immunology 9, e1226
- Duan Q, Zhang H, Zheng J and Zhang L (2020) Turning cold into hot: firing up the tumor microenvironment. Trends Cancer 6, 605-618 https://doi.org/10.1016/j.trecan.2020.02.022
- Zhang J, Huang D, Saw PE and Song E (2022) Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol 43, 523-545 https://doi.org/10.1016/j.it.2022.04.010
- Kaufman HL, Kohlhapp FJ and Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14, 642-662 https://doi.org/10.1038/nrd4663
- Li K, Zhang Z, Mei Y et al (2022) Targeting the innate immune system with nanoparticles for cancer immunotherapy. J Mater Chem B 10, 1709-1733 https://doi.org/10.1039/D1TB02818A
- Bazak R, Houri M, El Achy S, Kamel S and Refaat T (2015) Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol 141, 769-784 https://doi.org/10.1007/s00432-014-1767-3
- Rosenbaum SR, Wilski NA and Aplin AE (2021) Fueling the fire: inflammatory forms of cell death and implications for cancer immunotherapy. Cancer Discov 11, 266-281 https://doi.org/10.1158/2159-8290.CD-20-0805
- Liu M, Wang L, Xia X et al (2022) Regulated lytic cell death in breast cancer. Cell Biol Int 46, 12-33 https://doi.org/10.1002/cbin.11705
- Chen GY and Nunez G (2010) Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10, 826-837 https://doi.org/10.1038/nri2873
- Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P and Vandenabeele P (2012) Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12, 860-875 https://doi.org/10.1038/nrc3380
- Ahmed A and Tait SWG (2020) Targeting immunogenic cell death in cancer. Mol Oncol 14, 2994-3006 https://doi.org/10.1002/1878-0261.12851
- Serrano-Del Valle A, Anel A, Naval J and Marzo I (2019) Immunogenic cell death and immunotherapy of multiple myeloma. Front Cell Dev Biol 7, 50
- Legrand AJ, Konstantinou M, Goode EF and Meier P (2019) The diversification of cell death and immunity: memento mori. Mol Cell 76, 232-242 https://doi.org/10.1016/j.molcel.2019.09.006
- Bustin M (1999) Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19, 5237-5246 https://doi.org/10.1128/MCB.19.8.5237
- Lui G, Wong CK, Ip M et al (2016) HMGB1/RAGE signaling and pro-inflammatory cytokine responses in non-HIV adults with active pulmonary tuberculosis. PLoS One 11, e0159132
- Li L and Lu YQ (2020) The regulatory role of high-mobility group protein 1 in sepsis-related immunity. Front Immunol 11, 601815
- Ge Y, Huang M and Yao YM (2021) The effect and regulatory mechanism of high mobility group box-1 protein on immune cells in inflammatory diseases. Cells 10, 1044
- Klune JR, Dhupar R, Cardinal J, Billiar TR and Tsung A (2008) HMGB1: endogenous danger signaling. Mol Med 14, 476-484 https://doi.org/10.2119/2008-00034.Klune
- Pandya UM, Egbuta C, Abdullah Norman TM et al (2019) The biophysical interaction of the danger-associated molecular pattern (DAMP) calreticulin with the pattern-associated molecular pattern (PAMP) lipopolysaccharide. Int J Mol Sci 20, 408
- Obeid M, Tesniere A, Panaretakis T et al (2007) Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 220, 22-34 https://doi.org/10.1111/j.1600-065X.2007.00567.x
- Wemeau M, Kepp O, Tesniere A et al (2010) Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 1, e104
- Obeid M, Tesniere A, Ghiringhelli F et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13, 54-61 https://doi.org/10.1038/nm1523
- Zunino B, Rubio-Patino C, Villa E et al (2016) Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene 35, 261-268 https://doi.org/10.1038/onc.2015.82
- Murshid A, Gong J and Calderwood SK (2012) The role of heat shock proteins in antigen cross presentation. Front Immunol 3, 63
- van Eden W, van der Zee R and Prakken B (2005) Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol 5, 318-330 https://doi.org/10.1038/nri1593
- Kovalchin JT, Mendonca C, Wagh MS, Wang R and Chandawarkar RY (2006) In vivo treatment of mice with heat shock protein, gp 96, improves survival of skin grafts with minor and major antigenic disparity. Transpl Immunol 15, 179-185 https://doi.org/10.1016/j.trim.2005.07.003
- Amores-Iniesta J, Barbera-Cremades M, Martinez CM et al (2017) Extracellular ATP Activates the NLRP3 inflammasome and is an early danger signal of skin allograft rejection. Cell Rep 21, 3414-3426 https://doi.org/10.1016/j.celrep.2017.11.079
- Venereau E, Ceriotti C and Bianchi ME (2015) DAMPs from cell death to new life. Front Immunol 6, 422
- Ghiringhelli F, Apetoh L, Tesniere A et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15, 1170-1178 https://doi.org/10.1038/nm.2028
- Kepp O, Bezu L, Yamazaki T et al (2021) ATP and cancer immunosurveillance. EMBO J 40, e108130
- Nyboe Andersen N, Pasternak B, Friis-Moller N, Andersson M and Jess T (2015) Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 350, h2809
- Parameswaran N and Patial S (2010) Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr 20, 87-103 https://doi.org/10.1615/CritRevEukarGeneExpr.v20.i2.10
- Cervera-Carrascon V, Siurala M, Santos JM et al (2018) TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology 7, e1412902
- Jiang C, Niu J, Li M, Teng Y, Wang H and Zhang Y (2014) Tumor vasculature-targeted recombinant mutated human TNF-alpha enhanced the antitumor activity of doxorubicin by increasing tumor vessel permeability in mouse xenograft models. PLoS One 9, e87036
- Egberts JH, Cloosters V, Noack A et al (2008) Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 68, 1443-1450 https://doi.org/10.1158/0008-5472.CAN-07-5704
- Cruceriu D, Baldasici O, Balacescu O and Berindan-Neagoe I (2020) The dual role of tumor necrosis factor-alpha (TNF-alpha) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol (Dordr) 43, 1-18 https://doi.org/10.1007/s13402-019-00489-1
- Zhang W, Borcherding N and Kolb R (2020) IL-1 signaling in tumor microenvironment. Adv Exp Med Biol 1240, 1-23 https://doi.org/10.1007/978-3-030-38315-2_1
- Chen L, Zheng L, Chen P and Liang G (2020) Myeloid differentiation primary response protein 88 (MyD88): the central hub of TLR/IL-1R signaling. J Med Chem 63, 13316-13329 https://doi.org/10.1021/acs.jmedchem.0c00884
- Nakamura K and Smyth MJ (2017) Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol 95, 325-332 https://doi.org/10.1038/icb.2016.126
- Chen CJ, Kono H, Golenbock D, Reed G, Akira S and Rock KL (2007) Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 13, 851-856 https://doi.org/10.1038/nm1603
- Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5, 375-386 https://doi.org/10.1038/nri1604
- Zhu Y, An X, Zhang X, Qiao Y, Zheng T and Li X (2019) STING: a master regulator in the cancer-immunity cycle. Mol Cancer 18, 152
- Vacchelli E, Sistigu A, Yamazaki T, Vitale I, Zitvogel L and Kroemer G (2015) Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. Oncoimmunology 4, e988042
- Zhang S, Kohli K, Black RG et al (2019) Systemic interferon-gamma increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial. Cancer Immunol Res 7, 1237-1243 https://doi.org/10.1158/2326-6066.CIR-18-0940
- Dovhey SE, Ghosh NS and Wright KL (2000) Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res 60, 5789-5796
- Gangaplara A, Martens C, Dahlstrom E et al (2018) Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment. PLoS Pathog 14, e1006985
- Coughlin CM, Salhany KE, Gee MS et al (1998) Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9, 25-34 https://doi.org/10.1016/S1074-7613(00)80585-3
- Sistigu A, Yamazaki T, Vacchelli E et al (2014) Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20, 1301-1309 https://doi.org/10.1038/nm.3708
- Karsch-Bluman A, Feiglin A, Arbib E et al (2019) Tissue necrosis and its role in cancer progression. Oncogene 38, 1920-1935 https://doi.org/10.1038/s41388-018-0555-y
- Koren E and Fuchs Y (2021) Modes of Regulated cell death in cancermodes of regulated cell death in cancer. Cancer Discov 11, 245-265 https://doi.org/10.1158/2159-8290.CD-20-0789
- Galluzzi L, Vitale I, Aaronson SA et al (2018) Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ 25, 486-541 https://doi.org/10.1038/s41418-017-0012-4
- Cai Z, Jitkaew S, Zhao J et al (2014) Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 16, 55-65 https://doi.org/10.1038/ncb2883
- Kaiser WJ, Sridharan H, Huang C et al (2013) Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem 288, 31268-31279 https://doi.org/10.1074/jbc.M113.462341
- Zhang Y, Chen X, Gueydan C and Han J (2018) Plasma membrane changes during programmed cell deaths. Cell Res 28, 9-21 https://doi.org/10.1038/cr.2017.133
- Gunther C, Martini E, Wittkopf N et al (2011) Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature 477, 335-339 https://doi.org/10.1038/nature10400
- Berghe TV, Linkermann A, Jouan-Lanhouet S, Walczak H and Vandenabeele P (2014) Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 15, 135-147 https://doi.org/10.1038/nrm3737
- Murphy JM, Czabotar PE, Hildebrand JM et al (2013) The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443-453 https://doi.org/10.1016/j.immuni.2013.06.018
- Aaes TL, Kaczmarek A, Delvaeye T et al (2016) Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep 15, 274-287 https://doi.org/10.1016/j.celrep.2016.03.037
- Park HH, Kim HR, Park SY et al (2021) RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment. Mol Cancer 20, 107
- Nicole L, Sanavia T, Cappellesso R et al (2022) Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3+ and CD8+ T cell density and predict prognosis in hepatocellular carcinoma. J Immunother Cancer 10, e004031
- Koo GB, Morgan MJ, Lee DG et al (2015) Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res 25, 707-725 https://doi.org/10.1038/cr.2015.56
- Snyder AG, Hubbard NW, Messmer MN et al (2019) Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci immunol 4, eaaw2004
- Werthmoller N, Frey B, Wunderlich R, Fietkau R and Gaipl US (2015) Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death Dis 6, e1761
- Jiang X, Stockwell BR and Conrad M (2021) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22, 266-282 https://doi.org/10.1038/s41580-020-00324-8
- Lewerenz J, Klein M and Methner A (2006) Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc-protects from oxidative glutamate toxicity. J Neurochem 98, 916-925 https://doi.org/10.1111/j.1471-4159.2006.03921.x
- Brigelius-Flohe R and Maiorino M (2013) Glutathione peroxidases. Biochim Biophys Acta 1830, 3289-3303 https://doi.org/10.1016/j.bbagen.2012.11.020
- Feng H and Stockwell BR (2018) Unsolved mysteries: how does lipid peroxidation cause ferroptosis? PLoS Biol 16, e2006203
- Dixon SJ, Lemberg KM, Lamprecht MR et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072 https://doi.org/10.1016/j.cell.2012.03.042
- Louandre C, Ezzoukhry Z, Godin C et al (2013) Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer 133, 1732-1742 https://doi.org/10.1002/ijc.28159
- Yang WS, SriRamaratnam R, Welsch ME et al (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317-331 https://doi.org/10.1016/j.cell.2013.12.010
- Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS and Stockwell BR (2016) Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A 113, E4966-E4975 https://doi.org/10.1073/pnas.1603244113
- Gaschler MM, Andia AA, Liu H et al (2018) FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol 14, 507-515 https://doi.org/10.1038/s41589-018-0031-6
- Manz DH, Blanchette NL, Paul BT, Torti FM and Torti SV (2016) Iron and cancer: recent insights. Ann N Y Acad Sci 1368, 149-161 https://doi.org/10.1111/nyas.13008
- Whitnall M, Howard J, Ponka P and Richardson DR (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 103, 14901-14906 https://doi.org/10.1073/pnas.0604979103
- Chen SJ, Kuo CC, Pan HY, Tsou TC, Yeh SC and Chang JY (2016) Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. Oncotarget 7, 49310-49321 https://doi.org/10.18632/oncotarget.10336
- Wang W, Green M, Choi JE et al (2019) CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270-274 https://doi.org/10.1038/s41586-019-1170-y
- Bordini J, Morisi F, Elia AR et al (2020) Iron induces cell death and strengthens the efficacy of antiandrogen therapy in prostate cancer models. Clin Cancer Res 26, 6387-6398 https://doi.org/10.1158/1078-0432.CCR-20-3182
- Zou Y, Palte MJ, Deik AA et al (2019) A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun 10, 1617
- Gout P, Buckley A, Simms C and Bruchovsky N (2001) Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc- cystine transporter: a new action for an old drug. Leukemia 15, 1633-1640 https://doi.org/10.1038/sj.leu.2402238
- Yu Y, Xie Y, Cao L et al (2015) The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol 2, e1054549
- Hassannia B, Vandenabeele P and Berghe TV (2019) Targeting ferroptosis to iron out cancer. Cancer Cell 35, 830-849 https://doi.org/10.1016/j.ccell.2019.04.002
- Wen Q, Liu J, Kang R, Zhou B and Tang D (2019) The release and activity of HMGB1 in ferroptosis. Biochem Biophys Res Commun 510, 278-283 https://doi.org/10.1016/j.bbrc.2019.01.090
- Ye F, Chai W, Xie M et al (2019) HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRAS(Q61L) cells. Am J Cancer Res 9, 730-739 https://doi.org/10.1186/s13046-019-1328-3
- Luo X, Gong HB, Gao HY et al (2021) Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. Cell Death Differ 28, 1971-1989 https://doi.org/10.1038/s41418-020-00719-2
- Raskov H, Orhan A, Christensen JP and Gogenur I (2021) Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer 124, 359-367 https://doi.org/10.1038/s41416-020-01048-4
- Efimova I, Catanzaro E, Van der Meeren L et al (2020) Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer 8, e001369
- Song J, Liu T, Yin Y et al (2021) The deubiquitinase OTUD1 enhances iron transport and potentiates host antitumor immunity. EMBO Rep 22, e51162
- Jiang Z, Lim S-O, Yan M et al (2021) TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest 131, e139434
- Wang W, Green M, Choi JE et al (2019) CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270-274 https://doi.org/10.1038/s41586-019-1170-y
- Lang X, Green MD, Wang W et al (2019) Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11 ferroptosis connects radiotherapy and immunotherapy. Cancer Discov 9, 1673-1685 https://doi.org/10.1158/2159-8290.CD-19-0338
- Wang H, Cheng Y, Mao C et al (2021) Emerging mechanisms and targeted therapy of ferroptosis in cancer. Mol Ther 29, 2185-2208 https://doi.org/10.1016/j.ymthe.2021.03.022
- Aglietti RA and Dueber EC (2017) Recent Insights into the molecular mechanisms underlying pyroptosis and gasdermin family functions. Trends Immunol 38, 261-271 https://doi.org/10.1016/j.it.2017.01.003
- Erkes DA, Cai W, Sanchez IM et al (2020) Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov 10, 254-269 https://doi.org/10.1158/2159-8290.CD-19-0672
- Yang D, He Y, Munoz-Planillo R, Liu Q and Nunez G (2015) Caspase-11 requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock. Immunity 43, 923-932 https://doi.org/10.1016/j.immuni.2015.10.009
- Fink SL and Cookson BT (2006) Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol 8, 1812-1825 https://doi.org/10.1111/j.1462-5822.2006.00751.x
- Yu P, Zhang X, Liu N, Tang L, Peng C and Chen X (2021) Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther 6, 1-21 https://doi.org/10.1038/s41392-020-00451-w
- Platnich JM and Muruve DA (2019) NOD-like receptors and inflammasomes: a review of their canonical and non-canonical signaling pathways. Arch Biochem Biophys 670, 4-14 https://doi.org/10.1016/j.abb.2019.02.008
- Shi J, Zhao Y, Wang Y et al (2014) Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514, 187-192 https://doi.org/10.1038/nature13683
- Hornung V, Ablasser A, Charrel-Dennis M et al (2009) AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458, 514-518 https://doi.org/10.1038/nature07725
- Chae JJ, Wood G, Masters SL et al (2006) The B30. 2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc Natl Acad Sci U S A 103, 9982-9987 https://doi.org/10.1073/pnas.0602081103
- Lu A, Magupalli Venkat G, Ruan J et al (2014) Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell 156, 1193-1206 https://doi.org/10.1016/j.cell.2014.02.008
- Liu X, Zhang Z, Ruan J et al (2016) Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535, 153-158 https://doi.org/10.1038/nature18629
- Kayagaki N, Stowe IB, Lee BL et al (2015) Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666-671 https://doi.org/10.1038/nature15541
- Shi J, Zhao Y, Wang K et al (2015) Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660-665 https://doi.org/10.1038/nature15514
- Wang Y, Gao W, Shi X et al (2017) Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 547, 99-103 https://doi.org/10.1038/nature22393
- Ding J, Wang K, Liu W et al (2016) Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535, 111-116 https://doi.org/10.1038/nature18590
- Jiang M, Qi L, Li L and Li Y (2020) The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer. Cell Death Discov 6, 1-11 https://doi.org/10.1038/s41420-020-00349-0
- Aizawa E, Karasawa T, Watanabe S et al (2020) GSDME-dependent incomplete pyroptosis permits selective IL-1α release under caspase-1 inhibition. iScience 23, 101070
- Zhang Z, Zhang Y, Xia S et al (2020) Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579, 415-420 https://doi.org/10.1038/s41586-020-2071-9
- Zhou Z, He H, Wang K et al (2020) Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science 368, eaaz7548
- Wang Q, Wang Y, Ding J et al (2020) A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature 579, 421-426 https://doi.org/10.1038/s41586-020-2079-1
- Li S, Chen P, Cheng B et al (2022) Pyroptosis predicts immunotherapy outcomes across multiple cancer types. Clin Immunol 245, 109163
- Pauken KE and Wherry EJ (2015) Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36, 265-276 https://doi.org/10.1016/j.it.2015.02.008
- Lu H, Dietsch GN, Matthews MA et al (2012) VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 18, 499-509 https://doi.org/10.1158/1078-0432.CCR-11-1625
- Dietsch GN, Lu H, Yang Y et al (2016) Coordinated activation of toll-like receptor8 (TLR8) and NLRP3 by the TLR8 agonist, VTX-2337, ignites tumoricidal natural killer cell activity. PLoS One 11, e0148764
- Monk BJ, Brady MF, Aghajanian C et al (2017) A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a gynecologic oncology group partners study. Ann Oncol 28, 996-1004 https://doi.org/10.1093/annonc/mdx049
- Gabrilovich DI and Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162-174 https://doi.org/10.1038/nri2506
- Coward J, Kulbe H, Chakravarty P et al (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17, 6083-6096 https://doi.org/10.1158/1078-0432.CCR-11-0945
- Dijkgraaf EM, Santegoets SJ, Reyners AK et al (2015) A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann Oncol 26, 2141-2149 https://doi.org/10.1093/annonc/mdv309
- Birmpilis AI, Paschalis A, Mourkakis A et al (2022) Immunogenic cell death, damps and prothymosin alpha as a putative anticancer immune response biomarker. Cells 11, 1415